Exposure- response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.
(2015) In British Journal of Clinical Pharmacology 80(6). p.1362-1373- Abstract
- AZD0837 is a novel oral anticoagulant investigated in clinical studies for stroke prevention in patients with atrial fibrillation (AF). It is bioconverted to its active form, AR-H067637, a potent, specific and reversible thrombin inhibitor.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/7749590
- author
- Lip, Gregory Y H ; Rasmussen, Lars H ; Olsson, Bertil LU ; Jensen, Eva ; Hamrén, Bengt ; Eriksson, Ulf and Wåhlander, Karin
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- British Journal of Clinical Pharmacology
- volume
- 80
- issue
- 6
- pages
- 1362 - 1373
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:26174611
- wos:000367470200012
- scopus:84957546562
- pmid:26174611
- ISSN
- 1365-2125
- DOI
- 10.1111/bcp.12719
- language
- English
- LU publication?
- yes
- id
- 988d0c32-9c6a-4a5d-b236-ddf693b03a3e (old id 7749590)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26174611?dopt=Abstract
- date added to LUP
- 2016-04-01 09:54:50
- date last changed
- 2022-04-12 00:07:28
@article{988d0c32-9c6a-4a5d-b236-ddf693b03a3e, abstract = {{AZD0837 is a novel oral anticoagulant investigated in clinical studies for stroke prevention in patients with atrial fibrillation (AF). It is bioconverted to its active form, AR-H067637, a potent, specific and reversible thrombin inhibitor.}}, author = {{Lip, Gregory Y H and Rasmussen, Lars H and Olsson, Bertil and Jensen, Eva and Hamrén, Bengt and Eriksson, Ulf and Wåhlander, Karin}}, issn = {{1365-2125}}, language = {{eng}}, number = {{6}}, pages = {{1362--1373}}, publisher = {{John Wiley & Sons Inc.}}, series = {{British Journal of Clinical Pharmacology}}, title = {{Exposure- response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.}}, url = {{http://dx.doi.org/10.1111/bcp.12719}}, doi = {{10.1111/bcp.12719}}, volume = {{80}}, year = {{2015}}, }